Leading Product Candidates
Spero Therapeutics is developing a portfolio of novel product candidates with the potential for meaningful patient impact and significant commercial applications. As a leader in the infectious disease field, we are highly committed to advancing new therapies for patients with serious infections. Our candidates are designed to treat MDR bacterial infections in both the hospital and community settings.
Talented Team of People with a Mission to Save Lives
Spero has been named one of the 2021 Best Places to Work by the Boston Business Journal.
-
Tebipenem HBr
Oral Candidate to Treat MDR Gram-Negative Infections
Novel antibiotic with the potential to be the first oral carbapenem for use in adults to treat complicated urinary tract infection and acute pyelonephritis.
-
SPR720
Oral Candidate to Treat Non-tuberculous Mycobacterial Disease
Novel agent with the potential to be the first oral antibiotic specifically approved for the treatment of NTM disease.
- Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients
- Spero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720
- Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis
- Spero Therapeutics to Present at Upcoming Investor Conferences
-
Investors
Learn about the investment opportunity, see our upcoming events and download our latest corporate presentation.
Investment opportunities > -
Careers
Join a passionate team that pushes the limits in finding innovative therapies to help patients.
Career opportunities > -
Partners
Our strategic partnerships foster mutually beneficial alliances that advance medicine to improve patient lives.
Partnership opportunities >
